Premium
A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF‐Inhibitor Mediated Attenuation of Bleomycin‐Induced Pulmonary Fibrosis
Author(s) -
Kulkarni Yogesh M.,
Dutta Sucharita,
Iyer Anand Krishnan V.,
Wright Clayton A.,
Ramesh Vani,
Kaushik Vivek,
Semmes Oliver John,
Azad Neelam
Publication year - 2018
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201700086
Subject(s) - idiopathic pulmonary fibrosis , pathogenesis , bleomycin , lipid metabolism , lipidomics , downregulation and upregulation , pulmonary fibrosis , fibrosis , medicine , cancer research , immunology , biology , pathology , bioinformatics , lung , biochemistry , chemotherapy , gene
Purpose Poor molecular characterization of idiopathic pulmonary fibrosis (IPF) has led to insufficient understanding of the pathogenesis of the disease, resulting in lack of effective therapies and poor prognosis. Particularly, the role of lipid imbalance due to impaired lipid metabolism in the pathogenesis of IPF has been poorly studied. Experimental design The authors have used shotgun lipidomics in a bleomycin (BLM) mouse model of pulmonary fibrosis with vascular endothelial growth factor (VEGF)‐inhibitor CBO‐P11 as a therapeutic measure, to identify a comprehensive set of lipids that contribute to the pathogenesis of pulmonary fibrosis. Results The authors report that attenuation of BLM‐induced fibrotic response with CBO‐P11 cotreatment is accompanied by a decrease in total lipid content and specific downregulation of lipids, which are upregulated in response to BLM treatment. Conclusion and clinical relevance Dysregulated lipids identified in this study hold the potential of being future biomarkers for IPF.